Bladder Cancer | Breakfast with the Investigators: Current and Future Management of Urothelial Bladder Carcinoma

1:00:16
 
Share
 

Manage episode 237512923 series 1464352
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.

Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Dr Daniel P Petrylak, Prof Thomas Powles and Dr Jonathan E Rosenberg.

  • Introduction (00:00)
  • Program overview: Dr Love
  • Current Role of Anti-PD-1/PD-L1 Antibodies in the Management of Advanced Urothelial Bladder Carcinoma (UBC) (1:13)
  • Case (Dr Petrylak): A woman in her mid-60s with metastatic UBC who experienced rapid disease progression on first-line gemcitabine/cisplatin (1:49)
  • Case (Dr Rosenberg): A man in his late 70s with metastatic UBC who was ineligible for cisplatin-based chemotherapy and achieved a complete response to first-line pembrolizumab (11:02)
  • Newly Approved and Investigational Novel Agents and Strategies Beyond Immune Checkpoint Inhibition (16:44)
  • Case (Dr Petrylak): A woman in her mid-60s with metastatic UBC who enrolled on a clinical trial of enfortumab vedotin and achieved a complete remission (24:42)
  • Case (Prof Powles): A man in his mid-60s with metastatic UBC whose disease progressed rapidly on gemcitabine/cisplatin and pembrolizumab who began treatment with enfortumab vedotin (28:09)
  • Future Applications of Anti-PD-1/PD-L1 Antibodies Alone or in Combination with Other Systemic Approaches (41:26)
  • Case (Dr Rosenberg): A woman in her early 60s with widespread metastatic UBC who experienced disease progression on single-agent nivolumab and was switched to nivolumab/ipilimumab (45:05)
  • Case (Prof Powles): A man in his mid-60s with transitional cell carcinoma who received neoadjuvant atezolizumab on a clinical trial (54:33)

Select publications

2175 episodes available. A new episode about every 0 hours averaging 74 mins duration .